Health information to help you understand symptoms. It isn't a diagnosis.
Check symptoms

Research deep dives

Anal cancer screening and early detection

Last reviewed November 16, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.

Anal cancer develops through recognizable precancerous stages, which means it is one of the cancers that can in principle be prevented rather than only treated.

Until recently, screening rested on reasoning by analogy with cervical cancer. In 2022 a large trial settled the central question, and guidelines have been catching up since.

Related pages: Anal cancer

The bottom line

What we know
  • Over 90 percent of anal cancers are caused by persistent high-risk HPV infection.
  • Treating high-grade anal lesions reduces progression to cancer.
  • High-resolution anoscopy is the examination that locates lesions for treatment.
  • Access to high-resolution anoscopy is limited, which constrains screening programmes.
What is still open
  • The best screening interval, which is not established and is extrapolated from cervical practice.
  • Whether screening benefits groups outside those studied in ANCHOR.

The story, step by step

  1. 1. ANCHOR ()
  2. 2. Who ()
  3. 3. The tests ()
  4. 4. Symptoms ()
  5. 5. Diagnosis ()
What the evidence labels mean
GuidelineAn official recommendation from an expert group after weighing all the evidence.
Review of many studiesCombines the results of many studies (a systematic review or meta-analysis).
Randomized trialPeople were randomly given a treatment or a comparison, the best way to test cause and effect.
Large observational studyFollows many people over time. Shows strong links, but not always cause and effect.
Small or early studyA small study, case series, or first results. Needs to be confirmed.
Lab or animal studyDone in cells or animals. May not apply to people.
Part 1 of 5

The trial that settled the question

Review of many studies

What happens

Why screening recommendations changed.

What the research shows

  • The ANCHOR study enrolled people with HIV aged 35 and over who had high-grade squamous intraepithelial lesions, and randomized them to treatment of the lesions or to active monitoring.
  • It was stopped early, in 2022, because treating the lesions reduced progression to anal cancer by about 57 percent compared with monitoring.
  • Before this, screening was based on the reasonable assumption that anal precancer behaves like cervical precancer. That assumption is now supported by direct evidence in at least one population.
  • The result is the reason guidelines now recommend organized screening for specific groups rather than leaving it to individual judgement.
  • It does not tell us whether screening helps groups outside the trial, or what the right interval is. Those remain extrapolations.

Why it matters

This moved anal cancer screening from plausible to evidence-based, which is a genuinely recent change that many clinicians and most patients have not heard about.

What's still uncertain

  • Whether the same benefit applies to people without HIV at elevated risk, who were not in the trial.

Read more

Next: Who

Part 2 of 5

Which groups, and from what age

Review of many studies

What happens

The current recommendations, which are newer than most people realize.

What the research shows

  • People with HIV are the highest-risk group. Guidelines recommend starting screening at age 35 for men who have sex with men and transgender women with HIV, and at 45 for other people with HIV.
  • Other groups considered for screening include people with a history of vulvar cancer or high-grade vulvar lesions, solid organ transplant recipients several years after transplant, and women with a history of cervical or vaginal high-grade lesions.
  • Men who have sex with men without HIV, and anyone with a history of receptive anal intercourse, are at elevated risk; recommendations here are less uniform and depend partly on local availability.
  • A history of genital warts is a marker of HPV exposure rather than a direct indication on its own.
  • Screening is not recommended for the general population. The disease is uncommon enough that population screening would produce more harm than benefit.
  • If you are in one of these groups and nobody has raised screening, asking is reasonable. Uptake is low even where guidelines are clear.

Why it matters

The groups are defined by persistent HPV risk and by immune status, which is why HIV sits at the centre of them.

What's still uncertain

  • Where to set thresholds for groups not represented in trials, which guidelines acknowledge as uncertain.

Read more

Next: The tests

Part 3 of 5

Cytology, DARE and high-resolution anoscopy

Review of many studies

What happens

What each one is and what it is for.

What the research shows

  • Anal cytology, sometimes called an anal Pap, is a swab of the anal canal read for abnormal cells. It takes seconds and is uncomfortable rather than painful.
  • An abnormal result leads to high-resolution anoscopy: a magnified examination of the anal canal after applying acetic acid and iodine, which make abnormal areas visible so they can be biopsied and treated.
  • HRA takes 15 to 30 minutes, is done awake in a clinic, and is uncomfortable. Treatment of lesions is often done at the same visit, usually with ablation.
  • Digital anal rectal examination, a gloved finger examination, is the minimum. It detects masses that cytology can miss entirely, and it is recommended annually in high-risk groups even where cytology is unavailable.
  • Cytology without access to HRA is of limited value, because an abnormal result then has nowhere to go. Trained HRA providers are scarce, and this is the practical bottleneck in screening.
  • Cytology results use the same terminology as cervical screening: ASC-US, LSIL, HSIL. HSIL on biopsy is the finding that triggers treatment.

Why it matters

If a clinic offers cytology, the question worth asking is where HRA is done if the result is abnormal.

What's still uncertain

  • The optimal screening interval, which is not established; annual to three-yearly is used depending on findings and risk.

Read more

Next: Symptoms

Part 4 of 5

Why early detection still mostly depends on you

Review of many studies

What happens

Most anal cancers are found because someone was investigated, not screened.

What the research shows

  • Bleeding is the most common symptom and is nearly always attributed to haemorrhoids, by patients and often by clinicians.
  • Other symptoms: a lump or mass at the anus, pain or pressure, itching that does not settle, discharge, a change in bowel habit, narrowing of the stool, or a lump in the groin.
  • Anything that does not resolve within a few weeks of treatment for haemorrhoids deserves a proper examination rather than a repeat prescription.
  • Embarrassment delays diagnosis in this cancer more than almost any other, and the delay is measured in months in several studies.
  • A clinician who does not examine you cannot diagnose this. An examination is the part that matters.

Why it matters

The single most useful sentence here is that haemorrhoids are common and so is being wrong about them.

What's still uncertain

  • How much of the delay in diagnosis is patient-side versus clinician-side, which studies attribute to both.

Read more

Next: Diagnosis

Part 5 of 5

Confirming it, and working out the stage

Review of many studies

What happens

What happens after a suspicious finding.

What the research shows

  • Diagnosis is made by biopsy, usually taken during examination under anaesthetic or at anoscopy.
  • Most anal cancers are squamous cell carcinomas, which is why they are treated completely differently from colorectal cancer, which is usually adenocarcinoma.
  • Staging uses examination, MRI of the pelvis, CT of the chest and abdomen, and often a PET-CT, which is particularly useful for assessing lymph nodes and for planning the radiation field.
  • HIV testing is part of the workup, because status affects supportive care planning even though outcomes with modern treatment are broadly similar.
  • Lymph nodes in the groin are commonly involved and are included in the treatment field rather than removed surgically.
  • The stage drives the radiation dose and field rather than the choice of treatment, because nearly all anal cancers are treated with chemoradiation rather than surgery.

Why it matters

Unlike most cancers, the staging here does not usually decide between surgery and radiation. It shapes how the radiation is delivered.

What's still uncertain

  • How far PET-CT changes outcomes as opposed to changing plans, which is better established for the latter.

Read more

More plain-language reading

See something wrong or unclear on this page? Suggest a correction. OwieClear is for education only and isn't medical advice.